Clinical features of acute viral hepatitis B in Korea: a multi-center study
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: The incidence of Hepatitis B has significantly declined since the introduction of an HBV vaccination program. The aim of this study was to investigate recent clinical features of acute viral hepatitis B (AVH-B) in Korea. Methods: A total of 2241 patients with acute viral hepatitis were enrolled and their data were collected from nine medical-centers between January 2006 and December 2009. Results: One hundred nineteen (5.3%) of the 2241 were diagnosed as AVH-B. Among 78 patients with AVH-B whose data were analyzed, 50 were male, and the mean age was 38.6 years. In an initial test, mean AST, ALT and total-bilirubin levels were 1296.2 IU/L, 2109.6 IU/L and 9.3 mg/dl,respectively. Positivity frequencies for HBeAg and anti-HBe were 55.1% and 67.9%, respectively, and the mean HBV DNA level was 5.2 log10 copies/ml. The mean length of hospitalization was 11.6 days. During follow-up, AST, ALT and total bilirubin levels were normalized or near-normalized in all patients without serious complications. Sixty-three of 66 (95.4%)patients showed HBsAg loss and 37 (56.1%) patients showed HBsAg seroconversion. Only 3 patients (4.5%) showed persistent hepatitis B viremia. There was no case of death or liver transplantation. Nine patients (11.3%) had received anti-viral agents and their clinical outcomes were not significantly different from those of patients treated without antiviral agents. Conclusions: The prevalence of AVH-B among acute hepatitis patients is relatively low in Korea. AVH-B infection can be cured without complications in almost all patients, regardless of antiviral treatment.
Abstract
Background/Aims: The incidence of Hepatitis B has significantly declined since the introduction of an HBV vaccination program. The aim of this study was to investigate recent clinical features of acute viral hepatitis B (AVH-B) in Korea. Methods: A total of 2241 patients with acute viral hepatitis were enrolled and their data were collected from nine medical-centers between January 2006 and December 2009. Results: One hundred nineteen (5.3%) of the 2241 were diagnosed as AVH-B. Among 78 patients with AVH-B whose data were analyzed, 50 were male, and the mean age was 38.6 years. In an initial test, mean AST, ALT and total-bilirubin levels were 1296.2 IU/L, 2109.6 IU/L and 9.3 mg/dl,respectively. Positivity frequencies for HBeAg and anti-HBe were 55.1% and 67.9%, respectively, and the mean HBV DNA level was 5.2 log10 copies/ml. The mean length of hospitalization was 11.6 days. During follow-up, AST, ALT and total bilirubin levels were normalized or near-normalized in all patients without serious complications. Sixty-three of 66 (95.4%)patients showed HBsAg loss and 37 (56.1%) patients showed HBsAg seroconversion. Only 3 patients (4.5%) showed persistent hepatitis B viremia. There was no case of death or liver transplantation. Nine patients (11.3%) had received anti-viral agents and their clinical outcomes were not significantly different from those of patients treated without antiviral agents. Conclusions: The prevalence of AVH-B among acute hepatitis patients is relatively low in Korea. AVH-B infection can be cured without complications in almost all patients, regardless of antiviral treatment.
참고문헌 (19)
- Kim WR, "Epidemiology of hepatitis B in the United States", Hepatology, 49, pp.28~34 (2009)
- Park NH, "Impacts of Vaccination on Hepatitis B Viral Infections in Korea over a 25-Year Period", INTERVIROLOGY, 53(1), pp.20~28, KARGER
- 강형민, "단일 병원에서 경험한 최근 급성 바이러스간염의 원인 및 임상 양상", Clinical and Molecular Hepatology, 13(4), pp.495~502 (2007), 대한간학회
- 임형준, "2000년대 초기의 국내 급성 B형 간염 발생 양상의 변화", 대한내과학회지, 69(6), pp.601~607 (2005), 대한내과학회
- Pan CQ, "Natural history and clinical consequences of hepatitis B virus infection", Int J Med Sci, 2, pp.36~40 (2005)
- Chang MH, "Hepatitis B virus infection", Semin Fetal Neonatal Med, 12, pp.160~167 (2007)
- Shiffman ML, "Management of acute hepatitis B", Clin Liver Dis, 14, pp.75~91 (2010)
- Shepard CW, "Hepatitis B virus infection: epidemiology and vaccination", Epidemiol Rev, 28, pp.112~125 (2006)
- Lavanchy D, "Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention", J Clin Virol, 34(1), pp.1~3 (2005)
- Ni YH, "Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies", Gastroenterology, 132, pp.1287~1293 (2007)
- Jang KM, "Seroepidemicologic survey on type B viral hepatitis in Inchon area", Korean J Med, 23, pp.1331~1336 (1983)
- Chae HB, "Current status of liver diseases in Korea: hepatitis B", Korean J Hepatol, 15(6), pp.13~24 (2009)
- Te HS, "Epidemiology of hepatitis B and C viruses: a global overview", Clin Liver Dis, 14, pp.1~21 (2010)
- Goldstein ST, "A mathematical model to estimate global hepatitis B disease burden and vaccination impact", Int J Epidemiol, 34, pp.1329~1339 (2005)
- Sako A, "Acute hepatitis B in Japan: Incidence, clinical practices and health policy", Hepatol Res, 41, pp.39~45 (2011)
- Arauz-Ruiz P, "Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America", J Gen Virol, 83, pp.2059~2073 (2002)
- Yuki N, "Long-term histologic and virologic outcomes of acute self-limited hepatitis B", Hepatology, 37, pp.1172~1179 (2003)
- Kumar M, "A randomized controlled trial of lamivudine to treat acute hepatitis B", Hepatology, 45, pp.97~101 (2007)
- Yu JW, "The study of efficacy of lamivudine in patients with severe acute hepatitis B", Dig Dis Sci, 55, pp.775~783 (2010)